
New Alliance Capital
Description
New Alliance Capital (NAC) is a private equity fund based in Shanghai, China, established in 2015. The firm positions itself as an investor across various stages, including early, growth, and pre-IPO investments. Its strategic focus lies in identifying high-growth companies that possess strong management teams and disruptive technologies. NAC primarily targets sectors critical to China's economic and technological advancement, specifically healthcare, Technology, Media, and Telecommunications (TMT), and advanced manufacturing, alongside other emerging industries.
The firm's investment philosophy emphasizes long-term partnerships with portfolio companies, aiming to provide not just capital but also strategic guidance to help them scale and achieve market leadership. While their portfolio on platforms like Crunchbase indicates approximately 15 investments to date, their approach suggests a selective process focused on companies poised for significant expansion and eventual public listing or acquisition. This multi-stage investment strategy allows them to support companies from their nascent phases through to maturity.
New Alliance Capital manages a total of $30 million across two distinct funds, with their most recent being New Alliance Capital Fund II. This fund size suggests a disciplined investment approach, likely involving participation in larger syndicated rounds for growth and pre-IPO stages, while potentially leading smaller, earlier-stage rounds. Based on their fund size and investment stages, typical first check sizes for New Alliance Capital are estimated to range from approximately $500,000 for early-stage ventures to around $5,000,000 for more mature growth-stage or pre-IPO opportunities. This range allows them to maintain a diversified portfolio while still making meaningful contributions to their investees.
Investor Profile
New Alliance Capital has backed more than 22 startups, with 6 new investments in the last 12 months alone. The firm has led 2 rounds, about 9% of its total and boasts 8 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series D, Series A rounds (top funding stages).
- Majority of deals are located in China, Israel, United States.
- Strong thematic focus on Biotechnology, Health Care, Medical.
- Led 1 rounds in the past year.
- Typical check size: $500K – $5M.
Stage Focus
- Series B (27%)
- Series D (27%)
- Series A (18%)
- Series C (9%)
- Series Unknown (9%)
- Seed (9%)
Country Focus
- China (73%)
- Israel (14%)
- United States (14%)
Industry Focus
- Biotechnology
- Health Care
- Medical
- Manufacturing
- Artificial Intelligence (Ai)
- Machine Learning
- Biopharma
- Software
- Health Diagnostics
- Pharmaceutical
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.